Patently-O

APRIL 16, 2024

Pharmaceutical innovators are voicing concern that these disclosures are increasingly being used as prior art to invalidate patents arising out of, or otherwise relating to, these trials, in a manner that threatens to disincentivize investment in pharmaceutical innovation. By Chris Holman Salix Pharms., Norwich Pharms. Norwich Pharms.

Art 75

Art Patent Journalism Publishing 75

JD Supra Law

NOVEMBER 17, 2022

Biotechnology company Regeneron Pharmaceuticals, Inc.

Patent 120

Patent 120

LexBlog IP

DECEMBER 21, 2023

STELARA® (ustekinumab) Four months after Janssen Biotech, Inc. 10,961,307 (“the ’307 Patent”), directed to methods of treating ulcerative colitis with ustekinumab, Biocon Biologics Inc. Both patents are assigned to Regeneron Pharmaceuticals, Inc., On December 14, 2023, Celltrion, Inc.

Patent 52

Patent Reporting Settlement Intellectual Property 52

IP Law 360

AUGUST 20, 2021

Regeneron Pharmaceuticals Inc. wants a New York federal judge to toss a suit claiming it used poached technology in its development and testing of COVID-19 vaccines and treatments, saying the company is protected by a legal safe harbor.

Patent 75

Patent Technology 75

LexBlog IP

JUNE 2, 2022

Late last week, Regeneron Pharmaceuticals, Inc. filed an antitrust complaint against Amgen Inc. Regeneron alleges that “Amgen is engaged in a persistent exclusionary campaign to deny patients the life-saving benefits of [] Regeneron’s cholesterol-reducing medication, Praluent® (alirocumab).”

Marketing 40

Marketing Marketing Business Branding 40

Bio Law Blog

APRIL 5, 2020

The development and deployment of diagnostic and pharmaceutical products on a short-enough timeline and wide-enough scale will require the marshaling of scientific resources to a degree perhaps unprecedented in history. Companies and regulatory agencies have taken drastic steps to speed up this timeline. There is reason for optimism.

Publishing 40

Publishing Reporting Designs Design 40

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. As noted above, companies are already taking advantage of these new designations.

Settlement 52

Settlement Litigation Marketing Marketing 52